Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The History and Future of Multidisciplinary Cancer Care.
LaVigne AW, Doss VL, Berizzi D, Johnston FM, Kiess AP, Kirtane KS, Moghanaki D, Roumeliotis M, Yang GQ, Viswanathan AN. LaVigne AW, et al. Among authors: kirtane ks. Semin Radiat Oncol. 2024 Oct;34(4):441-451. doi: 10.1016/j.semradonc.2024.07.006. Semin Radiat Oncol. 2024. PMID: 39271279 Review. No abstract available.
Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis.
Saba NF, Chaudhary R, Kirtane K, Marra A, Ekpenyong A, McCook-Veal A, Schmitt NC, Gross JH, Patel MR, Remick J, Bates JE, McDonald MW, Rudra SF, Stokes WA, Biernacki M, Song X, Slebos RJC, Liu Y, Steuer CE, Shin DM, Teng Y, Chung CH. Saba NF, et al. Among authors: kirtane k. Clin Cancer Res. 2024 Oct 15;30(20):4601-4608. doi: 10.1158/1078-0432.CCR-24-1202. Clin Cancer Res. 2024. PMID: 39167623 Clinical Trial.
T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.
Gainor JF, Patel MR, Weber JS, Gutierrez M, Bauman JE, Clarke JM, Julian R, Scott AJ, Geiger JL, Kirtane K, Robert-Tissot C, Coder B, Tasneem M, Sun J, Zheng W, Gerbereux L, Laino A, Porichis F, Pollard JR, Hou P, Sehgal V, Chen X, Morrissey M, Daghestani HN, Feldman I, Srinivasan L, Frederick JP, Brown M, Aanur P, Meehan R, Burris HA 3rd. Gainor JF, et al. Among authors: kirtane k. Cancer Discov. 2024 Nov 1;14(11):2209-2223. doi: 10.1158/2159-8290.CD-24-0158. Cancer Discov. 2024. PMID: 39115419 Clinical Trial.
Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities.
Lozac'hmeur A, Danek T, Yang Q, Rosasco MG, Welch JS, Go WY, Ng EW, Mardiros A, Maloney DG, Garon EB, Kirtane K, Simeone DM, Molina JR, Salahudeen AA, Stein MM, Hecht JR. Lozac'hmeur A, et al. Among authors: kirtane k. NPJ Precis Oncol. 2024 Aug 5;8(1):174. doi: 10.1038/s41698-024-00665-z. NPJ Precis Oncol. 2024. PMID: 39103508 Free PMC article.
Molecular characterization of the salivary adenoid cystic carcinoma immune landscape by anatomic subsites.
Tasoulas J, Schrank TP, Bharambe H, Mehta J, Johnson S, Divaris K, Hackman TG, Sheth S, Kirtane K, Hernandez-Prera JC, Chung CH, Yarbrough WG, Ferrarotto R, Issaeva N, Theocharis S, Amelio AL. Tasoulas J, et al. Among authors: kirtane k. Sci Rep. 2024 Jul 9;14(1):15821. doi: 10.1038/s41598-024-66709-3. Sci Rep. 2024. PMID: 38982149 Free PMC article.
Author Correction: Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial.
Saba NF, Steuer CE, Ekpenyong A, McCook-Veal A, Magliocca K, Patel M, Schmitt NC, Stokes W, Bates JE, Rudra S, Remick J, McDonald M, Abousaud M, Tan AC, Fadlullah MZH, Chaudhary R, Muzaffar J, Kirtane K, Liu Y, Chen GZ, Shin DM, Teng Y, Chung CH. Saba NF, et al. Among authors: kirtane k. Nat Med. 2024 Aug;30(8):2373. doi: 10.1038/s41591-024-03161-w. Nat Med. 2024. PMID: 38956200 No abstract available.
Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Park R, Li J, Slebos RJC, Chaudhary R, Poole MI, Ferraris C, Farinhas J, Hernandez-Prera J, Kirtane K, Teer JK, Song X, Hall MS, Tasoulas J, Amelio AL, Chung CH. Park R, et al. Among authors: kirtane k. Oral Oncol. 2024 Jul;154:106866. doi: 10.1016/j.oraloncology.2024.106866. Epub 2024 May 30. Oral Oncol. 2024. PMID: 38820888 Clinical Trial.
Patient-Reported Outcomes among Multiple Myeloma Patients Treated with Standard of Care Idecabtagene Vicleucel.
Oswald LB, Gudenkauf LM, Li X, De Avila G, Peres LC, Kirtane K, Gonzalez BD, Hoogland AI, Nguyen O, Rodriguez Y, Baz RC, Shain KH, Alsina M, Locke FL, Freeman C, Castaneda Puglianini O, Nishihori T, Liu H, Blue B, Grajales-Cruz A, Jim HSL, Hansen DK. Oswald LB, et al. Among authors: kirtane k. Cancers (Basel). 2023 Sep 25;15(19):4711. doi: 10.3390/cancers15194711. Cancers (Basel). 2023. PMID: 37835405 Free PMC article.
41 results